The world’s need for radiopharmaceuticals is growing steadily as molecular imaging is becoming a key diagnostic tool in identifying a growing number of neurological, heart disease and cancers. A significant driver of this compelling growth as well as greater utilization of molecular imaging will be the development of new and more specific biomarkers.

That’s why NuView Life Sciences sponsors research with some of the world’s leading university researchers to develop specific molecular biomarkers that will allow physicians to transition from treating the illness to treating the individual.

Research in the areas of infectious disease, pancreatic cancer, breast cancer and prostrate cancer are just some of the exciting research programs that NuView now sponsors.

We are about to enter an era of extraordinary change where these new biomarkers will expand the boundaries of molecular imaging procedures such as Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT).

By altering the half life of these biomarkers, we can turn them into targeted therapies that provide unlimited possibilities and market positioning opportunities for personalized medicine.

Our understanding and commitment to this evolving sector of molecular medicine makes NuView much more than just a manufacturing and distribution business. NuView becomes a total solution provider to its targeted customers and markets.

NuView can provide you with a sustainable competitive advantage, by offering products and solutions that include PET scanners, automated dose delivery systems, radiopharmaceuticals that help you expand your efficiencies and increase profitability.